1. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.

2. Myasoedova E, Matteson EL. Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis. Curr Opin Rheumatol 2024;36:203–208.

3. Kim H, Cho SK, Song YJ, et al. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single-center prospective cohort. Arthritis Res Ther 2023;25:43.

4. Joy GM, Arbiv OA, Wong CK, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 2023;32:220210.

5. Lee SK, Shin K, Jung JY, Suh CH, Kim JW, Kim HA. Retention rate and safety of biologic and targeted synthetic DMARDs in patients with RA-associated interstitial lung disease: a KOBIO registry study. BioDrugs 2023;37:247–257.

6. Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk/prognostic factors, and treatment landscape. Clin Exp Rheumatol 2021;39:1108–1118.

7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.

8. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–1588.

9. Travis WD, Costabel U, Hansell DM, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–748.

10. Kim H, Sung YK. Epidemiology of rheumatoid arthritis in Korea. J Rheum Dis 2021;28:60–67.

11. Kim K, Woo A, Park Y, et al. Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis 2022;16:17534666221135314.

12. Albrecht K, Strangfeld A, Marschall U, Callhoff J. Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020. RMD Open 2023;9:e002777.

13. Molteni E, Adinolfi A, Bondi V, et al. Novel insights into the management of rheumatoid arthritis: one year in review 2024. Clin Exp Rheumatol 2024;42:947–960.

14. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res 2020;21:32.

15. Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol 2019;38:1109–1116.

16. Chang SH, Lee JS, Ha YJ, et al. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 2023;62:3014–3024.

17. Matson SM, Baqir M, Moua T, et al. Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory. Chest 2023;163:861–869.

18. Solomon JJ, Danoff SK, Woodhead FA, et al.; TRAIL1 Network Investigators. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 2023;11:87–96.

19. Matteson EL, Aringer M, Burmester GR, Mueller H, Moros L, Kolb M. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clin Rheumatol 2023;42:2311–2319.

20. Joung KI, Park H, Park S, Shin JY, Kim YH. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study. BMC Pulm Med 2023;23:98.

21. Juge PA, Hayashi K, McDermott GC, et al. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum 2024;64:152312.

22. Xie M, Zhu C, Ye Y. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. BMC Pulm Med 2023;23:255.

23. Chen N, Diao CY, Gao J, Zhao DB. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Semin Arthritis Rheum 2022;55:152004.

24. Li L, Liu R, Zhang Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2020;39:1457–1470.

25. Ito Y, Ichikawa Y, Murashima S, Sakuma H, Nakajima A. Rheumatoid arthritis disease activity significantly impacts on the severity of interstitial lung disease. Arthritis Res Ther 2024;26:95.

26. Matteson EL, Matucci-Cerinic M, Kreuter M, et al. Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review. RMD Open 2023;9:e003059.

27. Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. Korean J Intern Med 2019;34:434–441.

28. Colak S, Tekgoz E, Gunes EC, et al. Clinical characteristics of patients with connective tissue disease-related interstitial lung disease: a retrospective analysis. Clin Rheumatol 2024;43:1693–1701.

29. Yuan H, Cui S, Yang L, et al. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open 2023;9:e003487.

30. Nishii Y, Okamoto M, Zaizen Y, et al. Successful treatment of a patient with drug-refractory rheumatoid arthritis-associated interstitial lung disease with upadacitinib: a case report. Medicina (Kaunas) 2023;59:1960.

31. Kalyoncu U, Bilgin E, Erden A, et al. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clin Exp Rheumatol 2022;40:2071–2077.

32. Tardella M, Di Carlo M, Carotti M, Giovagnoni A, Salaffi F. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression. Clin Rheumatol 2021;40:4861–4867.

33. Tsujii A, Isoda K, Yoshimura M, et al. Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study. BMC Rheumatol 2024;8:4.

34. Sahin D, Colaklar A, Baysal S, et al. Rheumatoid arthritis-related lung disease and its association with mortality. J Clin Rheumatol 2024;30:177–182.

35. Román Ivorra JA, Trallero-Araguas E, Lopez Lasanta M, et al. Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning. RMD Open 2024;10:e003353.

36. Kim JW, Shin K, Jung J, et al. Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO registry. Clin Exp Rheumatol 2024;42:1781–1791.

37. Ng KH, Chen DY, Lin CH, Chao WC, Chen HH. Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan. RMD Open 2022;8:e002343.

38. Natalini JG, Swigris JJ, Morisset J, et al. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respir Med 2017;127:1–6.